NuVision Biotherapies Limited, a regenerative wound treatment company, and Altacor, a leading ophthalmic specialist, have announced the signing of a strategic partnership to distribute the sight saving therapy, Omnigen, throughout England, Scotland and Wales.
Through this agreement, Altacor will act as the exclusive distributor for the Omnigen product range to healthcare customers, with NuVision providing expert technical, scientific and clinical support. This unique offering of strong UK-based pharma and regenerative medicine is a milestone for ocular surface medicine, and for the future development and dissemination of personalised regenerative therapies.
Dr Andrew Hopkinson, founder and CEO of NuVision, said: “NuVision has partnered with Altacor to provide widespread access to Omnigen for Ophthalmology departments and patients across the country. Since our launch last year, we have already demonstrated significant successes in a small number of NHS and private hospitals in England, using Omnigen to help restore and retain patients sight. Surgeons have found Omnigen to be extremely convenient, easy to use, and effective in the treatment of ocular surface disorders. Through this partnership we will widen access to Omnigen across Great Britain, helping clinicians to save sight and the NHS to save money.
“We are excited to be working with Altacor who share our values of responsive and compassionate patient care. Together, we look forward to offering this groundbreaking regenerative therapy and high quality personal service to every ophthalmic surgeon in Great Britain”
Dr Francesca Crawford, CEO of Altacor, said: “This is a very significant partnership for Altacor which further expands our portfolio in the ophthalmic surgical area, adding to the viscoelastic Biolon and other imminent new launches. Omnigen is a fascinating and pioneering product which we are delighted to be working with, especially in light of the multiplicity of applications and the potential for sight saving. The complementarity and cooperation between the NuVision and Altacor teams is very strong and we believe will lead to great success.”
Dr Susan Huxtable, Director of IP Commercialisation at The University of Nottingham said: “NuVision has come a long way in a very short period of time and has already benefitted patients. I am delighted that the company has now secured this distribution deal with Altacor, which will help to ensure that the technology reaches many more patients, fully realising the impact of many years of academic research.”
Peter Dines, Investment Director and Head of Life Sciences at Mercia Fund Management, said: “We are pleased to see NuVision develop this key partnership with Altacor as they continue to commercialise Omnigen and increase access to this innovative treatment.”
To find out more about NuVision, please click here.